Emerging Therapies Plaque Psoriasis

>

Latest News

FDA Approves Adalimumab-aacf for Plaque Psoriasis, Hidradenitis Suppurativa and Other Conditions
FDA Approves Adalimumab-aacf for Plaque Psoriasis, Hidradenitis Suppurativa and Other Conditions

December 15th 2022

A biologic from Germany offers a new treatment option for a number of dermatologic conditions.

Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence
Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence

October 22nd 2022

Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022
Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022

March 25th 2022

Phase 3 Tapinarof Data Released
Phase 3 Tapinarof Data Released

December 8th 2021

Psoriasis
C-Jun Protein Linked to Psoriasis

June 22nd 2021

More News

Phase 3 results show risankizumab outperforms secukinumab

Phase 3 results show risankizumab outperforms secukinumab

Heather Onorati
January 17th 2020

Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.

patches of dry, flaky skin on knees

Leg psoriasis improves with topical lotion

Cheryl Guttman Krader, BS, Pharm
January 9th 2020

Topical halobetasol propionate 0.01% lotion appears to safely and quickly improve lower-extremity psoriatic lesions, according to a recent study.

<12
© 2024 MJH Life Sciences

All rights reserved.